Experimental drug aims to reverse liver scarring in NASH cirrhosis
Disease control
Completed
This phase 2b trial tests whether efruxifermin, an experimental drug, can improve liver fibrosis (scarring) without worsening inflammation in people with compensated cirrhosis due to NASH. Participants receive either efruxifermin or a placebo for up to 96 weeks. The main goal is …
Phase: PHASE2 • Sponsor: Akero Therapeutics, Inc • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC